| Literature DB >> 27603204 |
Ming-Kuei Lu1,2,3, Chun-Ming Chen3,4, Jeng-Ren Duann5,6, Ulf Ziemann7, Jui-Cheng Chen1,2,3, Shang-Ming Chiou2,8, Chon-Haw Tsai1,2,3.
Abstract
Parkinson's disease (PD) and essential tremor (ET) are characterized with motor dysfunctions. Motor circuit dysfunctions can be complementarily investigated by paired associative stimulation (PAS)-induced long-term potentiation (LTP)-like plasticity and diffusion tensor imaging (DTI) of the corticospinal tract (CST). Three groups of twelve subjects with moderate severity PD, ET with intention tremor and healthy controls (HC) were studied. The primary motor cortex (M1) excitability, measured by motor evoked potential (MEP) amplitude and by short-interval and long-interval intracortical inhibition (SICI and LICI) was compared between the three groups before and after PAS. The DTI measures of fractional anisotropy (FA) and mean diffusivity (MD) were acquired. PAS effects and DTI data were simultaneously examined between groups. PAS increased MEP amplitude in HC but not in PD and ET. SICI and LICI were significantly reduced after PAS irrespective of groups. No significant differences of the mean FA and MD were found between groups. There was no significant correlation between the PAS effects and the DTI measures. Findings suggest that both PD and ET with intention tremor have impairment of the associative LTP-like corticospinal excitability change in M1. The microstructure of the CST is not relevant to the deficiency of M1 associative plasticity in PD and ET.Entities:
Mesh:
Year: 2016 PMID: 27603204 PMCID: PMC5014415 DOI: 10.1371/journal.pone.0162265
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and clinical characteristics of the PD and ET patients.
| 1 | 67 | M | 9 | 18/4 | 2 | R | Levodopa 300, amantadine 300, trihexyphenidyl 3, entacapone 600 |
| 2 | 61 | M | 3 | 35/6 | 2.5 | R | Levodopa 200, amantadine 200 |
| 3 | 49 | F | 2 | 28/4 | 2.5 | R | Levodopa 600, pramipexole 0.75 |
| 4 | 81 | M | 2 | 19/5 | 2.5 | L | Levodopa 200, amantadine 100, trihexyphenidyl 4 |
| 5 | 72 | M | 5 | 38/4 | 2.5 | E | Levodopa 600, amantadine 300 |
| 6 | 60 | F | 0.5 | 18/8 | 2 | L | Levodopa 200, biperiden 4 |
| 7 | 74 | M | 2 | 17/2 | 2 | L | Levodopa 200 |
| 8 | 74 | M | 1 | 20/5 | 2 | L | Levodopa 100, trihexyphenidyl 4 |
| 9 | 68 | M | 2 | 13/4 | 2 | L | Levodopa 300, ropinirole 0.75 |
| 10 | 69 | M | 2 | 19/3 | 2 | E | Levodopa 300, amantadine 100 |
| 11 | 59 | M | 6 | 27/17 | 2 | R | Levodopa 300, amantadine 300, pramipexole 0.75 |
| 12 | 59 | M | 5 | 27/4 | 2.5 | L | Levodopa 600, amantadine 150, pramipexole 0.75 |
| 1 | 52 | F | > 10 | 1 | E | None | |
| 2 | 62 | M | 7 | 1 | L | Propranolol 20 | |
| 3 | 69 | M | > 20 | 2 | E | Clonazepam 0.25 | |
| 4 | 50 | M | > 10 | 1 | E | Propranolol 30, fludiazepam 0.75 | |
| 5 | 63 | M | > 10 | 1 | E | None | |
| 6 | 60 | M | > 30 | 2 | E | Propranolol 15, clonazepam 0.75 | |
| 7 | 81 | F | > 20 | 2 | E | None | |
| 8 | 65 | F | 5 | 1 | E | None | |
| 9 | 65 | F | > 20 | 1 | R | Propranolol 20 | |
| 10 | 67 | F | > 20 | 2 | E | Clonazepam 1 | |
| 11 | 74 | F | > 20 | 2 | E | Propranolol 30, clonazepam 0.75 | |
| 12 | 74 | M | > 20 | 2 | E | None |
* The score includes assessments for resting and action tremor.
** The score was based on the finger-nose-finger test: 0 = no intention tremor; 1 = probable intention component; 2 = definite intention component; 3 = functionally incapacitated due to intention tremor (Deuschl et al., 2000).
Abbreviations: E: equally affected, F: female, L: left, M: male, R: right
Baseline measures of transcranial magnetic stimulation (TMS) and median nerve somatosensory-evoked potential (SEP).
| RMT (%MSO) | AMT (%MSO) | MEP1mV | Conditional TMS intensity for SICI (%MSO) | Conditional TMS intensity for LICI (%MSO) | N20 latency (ms) | N20-P25 amplitude (μV) | |
|---|---|---|---|---|---|---|---|
| 51.9±7.2 | 41.8±6.3 | 74.7±11.3 | 41.8±6.4 | 61.9±9.6 | 19.8±1.3 | 3.9±3.0 | |
| 48.8±7.6 | 41.3±6.1 | 63.3±15.8 | 40.9±5.9 | 56.1±8.7 | 20.7±0.7 | 4.5±1.8 | |
| 48.8±9.5 | 41.2±6.0 | 63.4±14.3 | 39.2±6.8 | 54.0±9.9 | 20.2±1.6 | 5.1±2.6 |
* The intensity of TMS producing MEPs of on average 1 mV in peak-to-peak amplitude in the resting abductor pollicis brevis (APB).
Abbreviations: AMT: active motor threshold; ET: essential tremor; HC: health control; LICI: long-interval intracortical inhibition; MSO: maximum stimulator output; PD: Parkinson’s disease; RMT: resting motor threshold; SICI: short-interval intracortical inhibition
RmANOVA of the PAS effect on TMS measures the motor cortical excitability.
| MEP | SICI | LICI | |||||
|---|---|---|---|---|---|---|---|
| | 1 | 3.03 | 0.091 | ||||
| | 2,33 | 1.45 | 0.25 | 0.054 | 0.95 | 0.87 | 0.43 |
| | 2,33 | 1.51 | 0.24 | 0.81 | 0.46 | ||
a2 levels (pre-PAS and post-PAS)
b3 levels (PD, ET and HC)
* P < 0.05
** P < 0.01